Highlights Lepu Biopharma Co., Ltd.

Equities

2157

CNE100004SM4

Market Closed - Hong Kong S.E. Other stock markets 01:38:35 13/05/2024 pm IST			5-day change	1st Jan Change
5.86 ^HKD	+0.51%		-8.58%	+39.19%

12/04	Keymed Biosciences Advances Solid Tumors Drug With First Patient Study	MT
27/03	Lepu Biopharma Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Keymed Biosciences Advances Solid Tumors Drug With First Patient Study	12/04	MT
Lepu Biopharma Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	27/03	CI
Lepu Biopharma's Pancreatic Cancer Drug Gets US FDA Fast-Track Designation	11/03	MT
Lepu Biopharma Co., Ltd. Receives Fast Track Designation by the Food and Drug Administration of the United States for the Treatment of Pancreatic Cancer	11/03	CI
Lepu Biopharma Shareholders to Vote Jan. 31 on Contract to Produce Drugs for Lepu Medical Technology	17/01	MT
Lepu Biopharma Co., Ltd. Announces Completion of Patient Enrollment of Pivotal Phase IIb Clinical Trial for MRG003 for the Treatment of R/M NPC	29/12	CI
Lepu Biopharma Co., Ltd. Announces Orphan-Drug Designation Granted by the FDA to MRG004A for the Treatment of Pancreatic Cancer	14/12	CI
Lepu Biopharma to Provide Drug Production Services to Lepu Medical Technology	14/11	MT
Lepu Biopharma Divests 15% Stake in Technical Services Provider	29/23/29	MT
China Medical System Holdings Limited entered into the equity transfer agreement to acquire 15% stake in Hangzhou HealSun Biopharm Co., Ltd. from Lepu Biopharma Co., Ltd. for approximately CNY 130 million.	29/23/29	CI
Lepu Biopharma Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	25/23/25	CI
Lepu Biopharma Seeks to Extend Validity of Secondary Listing in Shanghai	09/23/09	MT
Lepu Biopharma Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	17/23/17	CI
Keymed and Lepu Biopharma Jointly Announces Global Exclusive Licence Agreement with Astrazeneca for Cmg901	23/23/23	CI
Keymed, Lepu Biopharma JV Signs License Deal with AstraZeneca for Cancer Treatment	23/23/23	MT
Lepu Biopharma Co., Ltd. Provides Update on the Data from Phase Ia Clinical Study of CMG901	05/23/05	CI
Luye Pharma's Boan Biotech Kicks Off Hong Kong IPO	19/22/19	MT
PW Medtech Group to Purchase Medical Device Components from Affiliate	14/22/14	MT
Lepu Biopharma Co., Ltd. Announces Conditional Marketing Approval Obtained in China Forpuyouheng (Pucotenlimab Injection) for Thetreatment of Inoperable or Metastatic Melanoma	29/22/29	CI
Lepu Biopharma Co., Ltd. Announces Breakthrough Therapy Designation Granted by the Center for Drug Evaluation to MRG003 for the Treatment of R/M NPC	29/22/29	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Lepu Biopharma Co., Ltd.

Equities

2157

CNE100004SM4

Highlights

Filters